StockData
COSCIENS Biopharma Inc. logo

COSCIENS Biopharma Inc. (CSCIF) stock

CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 20-F on Mar 25, 2026Score 1/30
$6.49+0.00 (0.00%)

Close on Oct 19, 2026Market cap $24.10MP/E –Yield –

COSCIENS Biopharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

COSCIENS Biopharma's ebitda for the twelve months ending Mar 31, 2026 was -$6.59M. For fiscal 2025 it was -$9.49M. The highest annual figure on record is $9.90M in fiscal 2018.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.49M–
FY2024Dec 31, 2024-$16.67M–
FY2023Dec 31, 2023-$3.19M-155.0%
FY2022Dec 31, 2022$5.79M–
FY2021Dec 31, 2021-$8.53M–
FY2020Dec 31, 2020-$5.47M–
FY2019Dec 31, 2019-$9.93M-200.3%
FY2018Dec 31, 2018$9.90M–
FY2017Dec 31, 2017-$22.98M–
FY2016Dec 31, 2016-$29.28M–
FY2015Dec 31, 2015-$34.61M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$389.00K–
Q4 FY2025Dec 31, 2025-$2.10M–
Q3 FY2025Sep 30, 2025-$2.04M–
Q2 FY2025Jun 30, 2025-$2.07M–
Q1 FY2025Mar 31, 2025-$2.33M–
Q4 FY2024Dec 31, 2024-$6.02M–
Q3 FY2024Sep 30, 2024-$5.81M–
Q2 FY2024Jun 30, 2024-$3.38M–
Q1 FY2024Mar 31, 2024-$1.46M–
Q4 FY2023Dec 31, 2023-$1.68M-109.9%
Q3 FY2023Sep 30, 2023-$748.00K–
Q2 FY2023Jun 30, 2023-$752.00K–
Q1 FY2023Mar 31, 2023-$4.17M–
Q4 FY2022Dec 31, 2022$16.93M–
Q3 FY2022Sep 30, 2022-$3.69M–
Q2 FY2022Jun 30, 2022-$4.68M–
Q1 FY2022Mar 31, 2022-$2.78M–
Q4 FY2021Dec 31, 2021-$3.09M–
Q3 FY2021Sep 30, 2021-$2.02M–
Q2 FY2021Jun 30, 2021-$2.12M–
Q1 FY2021Mar 31, 2021-$1.29M–
Q4 FY2020Dec 31, 2020-$1.21M–
Q3 FY2020Sep 30, 2020-$1.70M–
Q2 FY2020Jun 30, 2020-$1.40M–
Q1 FY2020Mar 31, 2020-$1.17M–
Q4 FY2019Dec 31, 2019-$1.70M–
Q3 FY2019Sep 30, 2019-$1.69M–
Q2 FY2019Jun 30, 2019-$3.66M–
Q1 FY2019Mar 31, 2019-$2.87M–
Q4 FY2018Dec 31, 2018-$3.03M–
Q3 FY2018Sep 30, 2018-$3.00M–
Q2 FY2018Jun 30, 2018-$3.48M–

More COSCIENS Biopharma figures

See a number that looks wrong?